(Q36961963)

17 August 2017

1 reference

title

Mu opioid receptor antagonists: recent developments (English)

1 reference

17 August 2017

Allan J Goodman

1

1 reference

17 August 2017

Bertrand Le Bourdonnec

series ordinal

2

1 reference

17 August 2017

Roland E Dolle

series ordinal

3

1 reference

17 August 2017

publication date

1 November 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

2

1 reference

17 August 2017

issue

11

1 reference

17 August 2017

page(s)

1552-1570

1 reference

Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

Naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

Three methods of opioid detoxification in a primary care setting. A randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

The treatment of heroin addiction: naltrexone alone and with behavior therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

Clonidine and naltrexone. A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

Emerging molecular approaches to pain therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Effect of mu opioid receptor blockade on alcohol intake in rats bred for high alcohol drinking.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Effect of selective antagonism of mu(1)-, mu(1/2)-, mu(3)-, and delta-opioid receptors on the locomotor-stimulating actions of ethanol.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Recent advances in selective opioid receptor agonists and antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

3-Alkyl ethers of clocinnamox: delayed long-term mu-antagonists with variable mu efficacy.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Synthesis and biological evaluation of 14-alkoxymorphinans. 2. (-)-N-(cyclopropylmethyl)-4,14-dimethoxymorphinan-6-one, a selective mu opioid receptor antagonist.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Synthesis and biological evaluation of 14-alkoxymorphinans. 3. Extensive study on cyprodime-related compounds

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

New structural concepts for narcotic antagonists defined in a 4-phenylpiperidine series

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Racemic and optically active 2,9-dimethyl-5-(m-hydroxyphenyl)morphans and pharmacological comparison with the 9-demethyl homologues.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Probes for narcotic receptor mediated phenomena. Part 28: new opioid antagonists from enantiomeric analogues of 5-(3-hydroxyphenyl)-N-phenylethylmorphan

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

N-substituted octahydro-4a-(3-hydroxyphenyl)-10a-methyl-benzo[g]isoquinolines are opioid receptor pure antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Structure-activity relationships of trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine antagonists for mu- and kappa-opioid receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Elucidation of the bioactive conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of mu-opioid receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

8-Carboxamidocyclazocine analogues: redefining the structure-activity relationships of 2,6-methano-3-benzazocines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

3-Carboxamido analogues of morphine and naltrexone. synthesis and opioid receptor binding properties

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

trans-3,4-dimethyl-4-(3-carboxamidophenyl)piperidines: a novel class of micro-selective opioid antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Toxicity from Lomotil. Accidental ingestion by a 22-month-old child

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Rapid detoxification of the narcotic addict with naloxone hydrochloride. A preliminary report

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Characteristics of pentazocine dependence in hospitalized patients after naloxone administration

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Oral naloxone reverses opioid-associated constipation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Oral naloxone in opioid-associated constipation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Naloxone in heroin dependence

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Naloxone reversal of buprenorphine-induced respiratory depression

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Naloxone in acute respiratory failure

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Alterations in response to somatic pain associated with anaesthesia. XXIII: Further study of naloxone

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Reversal of morphine anesthesia with naloxone.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Naloxone applied to conjunctiva as a test for physical opiate dependence

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Letter: Naloxone for propoxyphene overdosage.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Continuous naloxone infusion for opiate poisoning in infancy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

The management of propoxyphene poisoning

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Treatment of propoxyphene overdosage with naloxone

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

A controlled trial of naloxone infusions for the pruritus of chronic cholestasis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Epidural-morphine-induced pruritus: propofol versus naloxone.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Effects of prolonged naloxone infusion in septic shock.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Naloxone and TRH in the treatment of shock and trauma: what future roles?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Continuous naloxone infusion in two neonates with septic shock

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

High-dose naloxone in tardive dyskinesia.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Naloxone in tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Naltrexone treatment for alcohol dependence

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Naltrexone and coping skills therapy for alcohol dependence. A controlled study

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Naltrexone for individuals with comorbid bipolar disorder and alcohol dependence

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Naltrexone exerts a favourable effect on plasma lipids in abstinent patients with alcohol dependence

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Naltrexone shortened opioid detoxification with buprenorphine

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

A controlled trial of propoxyphene and naltrexone in patients with tourette's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Prophylactic oral naltrexone with intrathecal morphine for cesarean section: effects on adverse reactions and analgesia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

The Role of Narcotic Antagonists in the Rehabilitation of Opiate Addicts: A Review of Naltrexone

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Studies of EN-1639A (Naltrexone): A New Narcotic Antagonist

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Narcotic antagonists in the treatment of opioid dependence: Review and commentary

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Clinical outcome with naltrexone

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Clinical Experience with Naltrexone

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Naltrexone: A Short-Term Treatment for Opiate Dependence

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Naltrexone and conventionality

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Buprenorphine suppresses heroin use by heroin addicts

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Nontolerance to the opioid antagonism of naltrexone

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Rapid transition from methadone maintenance to naltrexone.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Randomised crossover trial of naltrexone in uraemic pruritus

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Naltrexone treatment of self-injurious thoughts and behaviors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Effects on naltrexone on infantile autism.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Naltrexone treatment for a 3-year-old boy with self-injurious behavior.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

High fat feeding is associated with increased blood pressure, sympathetic nerve activity and hypothalamic mu opioid receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

beta-Endorphin is associated with overeating in genetically obese mice (ob/ob) and rats (fa/fa)

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Resistance to diet-induced obesity in mu-opioid receptor-deficient mice: evidence for a "thrifty gene".

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Opioids and food intake: distributed functional neural pathways?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Endogenous opiates and energy balance

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Central administration of the opioid antagonist, LY255582, decreases short- and long-term food intake in rats

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Alvimopan for the management of postoperative ileus

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

A review of the potential role of methylnaltrexone in opioid bowel dysfunction

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Peripherally restricted opioid agonists as novel analgesic agents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Alvimopan∗∗Alvimopan is the official USAN name adopted as of press time. (ADL 8-2698) Is a Novel Peripheral Opioid Antagonist

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.200700143

1 reference

7 January 2021

Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Synthesis of trans-3,4-Dimethyl-4-(3-hydroxyphenyl)piperidine Opioid Antagonists: Application of the Cis-Thermal Elimination of Carbonates to Alkaloid Synthesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

SAR and biological evaluation of novel trans-3,4-dimethyl-4-arylpiperidine derivatives as opioid antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Clinical uses of naltrexone: a review of the evidence

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700143

7 January 2021

Identifiers

DOI

10.1002/CMDC.200700143

1 reference

17 August 2017

1 reference